March 29, 2024
Atonco and University of Michigan Announce Collaboration on Phase 1-2a Clinical Study of ATO-101™
Atonco, a French biotechnology company, and University of Michigan Health today announced a collaborative agreement to conduct a Phase 1-2a clinical study evaluating Atonco's ATO-101™ ([211At] At-anti-CA-IX antibody) targeted alpha therapy candidate in non-muscle invasive bladder cancer (NMIBC).